You just read:

Hospira Shares Results From Randomised Trials Showing Biosimilar Monoclonal Antibody, Inflectra™, Demonstrates Comparable Reductions in Disease Activity to Remicade® Over One Year

News provided by

Hospira

13 Jun, 2014, 11:21 BST